We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > Vividion

News List

Vividion Therapeutics officially withdraws $100 million IPO following acquisition by Bayer firstwordpharma
August 23, 2021
Vividion Therapeutics withdrew its plans for an initial public offering after announcing earlier this month that it would be acquired by Bayer for up to $2 billion, Renaissance Capital reported.
Bayer to acquire Vividion for $1.5bn to boost drug discovery platform pharmaceutical-technology
August 05, 2021
Bayer is set to acquire US-based biopharmaceutical company Vividion Therapeutics at a deal totalling up to $2bn to boost its drug discovery expertise and expand into new modalities.
Healthcare industry reported 85 deals worth $30 billion in Feb 2021 expresspharma
March 08, 2021
In February 2021, the healthcare industry reported 85 deals worth $30 billion as compared to last 12-month average (February 2020 to January 2021) of 88 deals worth $17.3 billion.
Celgene to tackle ‘undruggable’ targets with Vividion pharmaphorum
March 06, 2018
Celgene has signed a deal with Vividion Therapeutics to develop drugs for oncology, inflammatory, and neurodegenerative diseases.